1 Study Coverage
1.1 Human Microbiome Therapeutic Drugs Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022) & (US$ Million) Introduction
1.2 Global Human Microbiome Therapeutic Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Human Microbiome Therapeutic Drugs Market Size for the Year 2017-2028
1.2.2 Global Human Microbiome Therapeutic Drugs Market Size for the Year 2017-2028
1.3 Human Microbiome Therapeutic Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Human Microbiome Therapeutic Drugs in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Human Microbiome Therapeutic Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Human Microbiome Therapeutic Drugs Market Dynamics
1.4.1 Human Microbiome Therapeutic Drugs Industry Trends
1.4.2 Human Microbiome Therapeutic Drugs Market Drivers
1.4.3 Human Microbiome Therapeutic Drugs Market Challenges
1.4.4 Human Microbiome Therapeutic Drugs Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Human Microbiome Therapeutic Drugs by Type
2.1 Human Microbiome Therapeutic Drugs Market Segment by Type
2.1.1 FMT
2.1.2 Microbiome Drugs
2.1.3 Others
2.2 Global Human Microbiome Therapeutic Drugs Market Size by Type (2017, 2022 & 2028)
2.3 Global Human Microbiome Therapeutic Drugs Market Size by Type (2017-2028)
2.4 United States Human Microbiome Therapeutic Drugs Market Size by Type (2017, 2022 & 2028)
2.5 United States Human Microbiome Therapeutic Drugs Market Size by Type (2017-2028)
3 Human Microbiome Therapeutic Drugs by Application
3.1 Human Microbiome Therapeutic Drugs Market Segment by Application
3.1.1 Stomach
3.1.2 Oral
3.1.3 Respiratory Tract
3.1.4 Others
3.2 Global Human Microbiome Therapeutic Drugs Market Size by Application (2017, 2022 & 2028)
3.3 Global Human Microbiome Therapeutic Drugs Market Size by Application (2017-2028)
3.4 United States Human Microbiome Therapeutic Drugs Market Size by Application (2017, 2022 & 2028)
3.5 United States Human Microbiome Therapeutic Drugs Market Size by Application (2017-2028)
4 Global Human Microbiome Therapeutic Drugs Competitor Landscape by Company
4.1 Global Human Microbiome Therapeutic Drugs Market Size by Company
4.1.1 Top Global Human Microbiome Therapeutic Drugs Companies Ranked by Revenue (2021)
4.1.2 Global Human Microbiome Therapeutic Drugs Revenue by Player (2017-2022)
4.2 Global Human Microbiome Therapeutic Drugs Concentration Ratio (CR)
4.2.1 Human Microbiome Therapeutic Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Human Microbiome Therapeutic Drugs in 2021
4.2.3 Global Human Microbiome Therapeutic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Human Microbiome Therapeutic Drugs Headquarters, Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022) & (US$ Million) Type
4.3.1 Global Human Microbiome Therapeutic Drugs Headquarters and Area Served
4.3.2 Global Human Microbiome Therapeutic Drugs Companies Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Human Microbiome Therapeutic Drugs Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Human Microbiome Therapeutic Drugs Market Size by Company
4.5.1 Top Human Microbiome Therapeutic Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Human Microbiome Therapeutic Drugs Revenue by Players (2020, 2021 & 2022)
5 Global Human Microbiome Therapeutic Drugs Market Size by Region
5.1 Global Human Microbiome Therapeutic Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Human Microbiome Therapeutic Drugs Market Size by Region (2017-2028)
5.2.1 Global Human Microbiome Therapeutic Drugs Market Size by Region: 2017-2022
5.2.2 Global Human Microbiome Therapeutic Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Human Microbiome Therapeutic Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Human Microbiome Therapeutic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Human Microbiome Therapeutic Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Human Microbiome Therapeutic Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Human Microbiome Therapeutic Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Human Microbiome Therapeutic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Human Microbiome Therapeutic Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Human Microbiome Therapeutic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Human Microbiome Therapeutic Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Human Microbiome Therapeutic Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Rebiotix
7.1.1 Rebiotix Company Details
7.1.2 Rebiotix Business Overview
7.1.3 Rebiotix Human Microbiome Therapeutic Drugs Introduction
7.1.4 Rebiotix Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.1.5 Rebiotix Recent Development
7.2 Seres Therapeutics
7.2.1 Seres Therapeutics Company Details
7.2.2 Seres Therapeutics Business Overview
7.2.3 Seres Therapeutics Human Microbiome Therapeutic Drugs Introduction
7.2.4 Seres Therapeutics Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.2.5 Seres Therapeutics Recent Development
7.3 Vedanta Biosciences
7.3.1 Vedanta Biosciences Company Details
7.3.2 Vedanta Biosciences Business Overview
7.3.3 Vedanta Biosciences Human Microbiome Therapeutic Drugs Introduction
7.3.4 Vedanta Biosciences Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.3.5 Vedanta Biosciences Recent Development
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Company Details
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Human Microbiome Therapeutic Drugs Introduction
7.4.4 Bristol-Myers Squibb Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.4.5 Bristol-Myers Squibb Recent Development
7.5 Johnson and Johnson
7.5.1 Johnson and Johnson Company Details
7.5.2 Johnson and Johnson Business Overview
7.5.3 Johnson and Johnson Human Microbiome Therapeutic Drugs Introduction
7.5.4 Johnson and Johnson Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.5.5 Johnson and Johnson Recent Development
7.6 Takeda
7.6.1 Takeda Company Details
7.6.2 Takeda Business Overview
7.6.3 Takeda Human Microbiome Therapeutic Drugs Introduction
7.6.4 Takeda Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.6.5 Takeda Recent Development
7.7 ENTEROME Bioscience
7.7.1 ENTEROME Bioscience Company Details
7.7.2 ENTEROME Bioscience Business Overview
7.7.3 ENTEROME Bioscience Human Microbiome Therapeutic Drugs Introduction
7.7.4 ENTEROME Bioscience Revenue in Human Microbiome Therapeutic Drugs Business (2017-2022)
7.7.5 ENTEROME Bioscience Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
